الفهرس 
Formulation and evaluation of modified release preparations
List of ContentsOnly 14 pages are availabe for public view
 |  | from | 163 |  |  |
| | | from | 163 | | |
Abstract
Dexibuprofen (DI) is a pharmaceutical enantiomer of ibuprofen with more potent action and lesser side effects. It has nonsteroidal anti-inflammatory, analgesic and antipyretic activity with moderate incidence of gastrointestinal side effects. It is widely used as analgesic and for the acute and long-term treatment of rheumatoid arthritis and osteoarthritis. DI belongs to class ll of the Biopharmaceutical classification system (BCS) which having low water solubility and high permeability, so the current work aims to enhance drug solubility, consequently its absorption which is the rate limiting step in drug bioavailability and to be suitable to be adminstered in the buccal cavity to avoid all the disadvantages of other routes of administration. Inclusion complexes (ICs) with hydroxypropyl-Ý-cyclodextrin (HP-Ý-CD) as well as spherical crystallization were used to overcome the challenge of poor DI solubility. Therefore, the work in this thesis is divided into two chapters. Chapter I : Improvement of solubility and dissolution of (DI) . Chapter II: Formulation and evaluation of freeze-dried capsules of the selected DI polymeric agglomerate crystals Chapter I: Improvement of solubility and dissolution of dexibuprofen. The objective of this chapter was to prepare DI - HP-Ý-CD inclusion complex using three different methods namely physical mixing, freeze drying and kneading. In addition, recrystallization of dexibuprofen by spherical agglomeration using acid-base neutralization method in presence of different water soluble polymers namely Polyvinylpyrrolidone, Hydroxypropyl beta cyclodextrin and Polyethylene glycol 4000